Editas Q1 2025 Earnings Report
Key Takeaways
Editas Medicine reported a net loss of $76.1 million for the first quarter of 2025, an increase from the $62.0 million net loss in the same period last year. Revenue from collaboration and other R&D increased, while R&D and G&A expenses decreased. The Company's cash position is expected to fund operations into the second quarter of 2027.
Net loss for Q1 2025 was $76.1 million, or $0.92 per share.
Collaboration and other R&D revenues increased to $4.7 million in Q1 2025.
Research and development expenses decreased to $26.6 million in Q1 2025, primarily due to the discontinuation of the reni-cel program.
General and administrative expenses decreased to $13.4 million in Q1 2025 due to lower stock-based compensation.
The Company's cash, cash equivalents, and marketable securities were $221.0 million as of March 31, 2025, with an expected operational runway into Q2 2027.
Editas
Editas
Editas Revenue by Segment
Forward Guidance
Editas Medicine expects its current cash, cash equivalents, and marketable securities to fund operations into the second quarter of 2027. The company is on track to declare two in vivo gene editing development candidates in mid-2025 and disclose an additional target cell type/tissue by the end of 2025.
Positive Outlook
- Expected cash runway into the second quarter of 2027.
- On track to declare two in vivo gene editing development candidates in mid-2025.
- Plan to establish and disclose one additional target cell type/tissue beyond HSCs and liver by year-end 2025.
- Upcoming preclinical data presentations at ASGCT and TIDES conferences.
- Continued progress in advancing in vivo gene editing programs.
Challenges Ahead
- Actual results or events could differ materially from forward-looking statements.
- Uncertainties inherent in the initiation and completion of preclinical studies.
- Availability and timing of results from preclinical studies are not guaranteed.
- Expectations for regulatory approvals to conduct trials may not be met.
- Availability of funding sufficient for operating expenses and capital expenditure requirements is subject to various factors.